Benitec Biopharma
BNTC12.4107.17% ( +0.830 )
Benitec Biopharma (BNTC)
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRN...
- Open
- 12.180
- High
- 12.420
- Low
- 11.655
- Prev. Close
- 11.580
- Volume
- 21.15K
- Turnover
- 255.38K
- Avg Price
- 12.077
- Bid/Ask Ratio
- --
- Amplitude
- 6.61%
- 52wk High
- 16.760
- Volume Ratio
- 0.62
- Turnover Ratio
- 0.12%
Benitec Biopharma Analyst Rating
View MoreForecast & Rating
Jul 28, 2026Price forecast
$24.1794.74%
Forecast & RatingStrong buy
7analysts
- Strong buy85.71%
- Buy14.29%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- benzinga_article · 2 hours ago
This Crowdstrike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
- Market Beat · 9 hours ago
Benitec Biopharma Limited (NASDAQ:BNTC) Given Average Recommendation of "Moderate Buy" by Analysts
- Tip Ranks · May 14 at 09:55 PM
Benitec Biopharma Reaffirmed at Buy on Strong Cash Runway and Clear BB-301 Pivotal Path in OPMD Dysphagia
- Earnings Watch · May 14 at 07:11 AM
Benitec Biopharma | 8-K: FY2026 Q3 Revenue: USD 0
- StockTitan · Apr 26 at 10:05 PM
PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors | BNTC Stock News
- Market Beat · Mar 9 at 11:50 AM
Benitec Biopharma's (BNTC) "Buy" Rating Reaffirmed at HC Wainwright
